LY4005130 not checked

Eli Lilly

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
3 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Vitiligo, Non-Segmental Vitiligo (NSV), Alopecia Areata
Main trialPhase 2
“The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 48 weeks, including screening.”In the company’s words, NCT07533019 on ClinicalTrials.gov

Other drugs for Vitiligo

All 13 drugs for Vitiligo

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting May 2027 A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase 2Recruiting Jun 2027 A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Phase 1Completed 28 Apr 2026 A Study of LY4005130 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LY4005130

Following is part of Solo: you see every change to LY4005130 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in